ABT · 10-Q · 2026Q3 · Full report
Exact Sciences Acquisition
ABBOTT LABORATORIES · 2026-11-04 · Importance 71 · Surprise 60 · Contradicted
Abbott completed its acquisition of Exact Sciences on March 23, 2026, for approximately $20.6 billion, paying $105 per common share in cash. Abbott funded the purchase primarily with $20.0 billion of long-term debt issued in March 2026 and the remainder with cash; it also assumed approximately $2.8 billion of target debt, nearly all of which it repaid. The acquisition established Abbott's position in cancer diagnostics and added Cologuard, Oncotype DX, and Cancerguard; Exact Sciences contributed approximately $2.0 billion of sales from the acquisition date through September 30. A third-quarter purchase-accounting adjustment increased acquired intangible assets by $3.2 billion and reduced goodwill by the same amount, resulting in approximately $100 million of additional third-quarter amortization expense.
Key facts
- On March 23, 2026, Abbott completed its acquisition of Exact Sciences for approximately $20.6 billion. source
- The preliminary purchase-price allocation for the Exact Sciences acquisition included $16.0 billion of acquired intangible assets, $8.9 billion of goodwill, $0.4 billion of acquired net tangible assets, $2.7 billion of deferred income taxes, and $2.0 billion of net debt, for a total fair value of $20.6 billion. source
- Abbott funded the Exact Sciences acquisition primarily by issuing $20.0 billion of long-term debt in March 2026, with the remainder funded with cash on hand. source
- In the third quarter of 2026, Abbott recorded a $3.2 billion increase in acquired intangible assets, with a corresponding reduction to goodwill, as a measurement-period adjustment for the Exact Sciences acquisition. source
- In the first nine months of 2026, Abbott’s consolidated results included $2.0 billion of net sales related to Exact Sciences. source
- From its March 23, 2026 acquisition date, Exact Sciences contributed approximately $2.0 billion of Diagnostic Products sales reported as Cancer Diagnostics. source
- Abbott completed its acquisition of Exact Sciences on March 23, 2026, for approximately $20.6 billion, funded primarily with $20.0 billion of long-term debt and the remainder with cash on hand. source
- Abbott’s unaudited pro forma consolidated net sales for the three and nine months ended September 30, 2025, assuming the Exact Sciences acquisition had occurred at the beginning of 2025, were approximately $12.2 billion and $35.2 billion, respectively. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | realized | +23.4% | The preliminary purchase-price allocation for the Exact Sciences acquisition included $16.0 billion of acquired intangible assets, $8.9… |
| liability | negative | realized | -18.5% | Abbott funded the Exact Sciences acquisition primarily by issuing $20.0 billion of long-term debt in March 2026, with the remainder funded… |
| revenue | positive | realized | +17.7% | Abbott’s unaudited pro forma consolidated net sales for the three and nine months ended September 30, 2026, were approximately $13.0… |
| revenue | positive | realized | +15.4% | From its March 23, 2026 acquisition date, Exact Sciences contributed approximately $2.0 billion of Diagnostic Products sales reported as… |
| liability | negative | realized | -4.3% | The preliminary purchase-price allocation for the Exact Sciences acquisition included $16.0 billion of acquired intangible assets, $8.9… |
| operating_income | negative | realized | -0.8% | In the third quarter of 2026, Abbott recorded a $3.2 billion increase in acquired Exact Sciences intangible assets with a corresponding… |